



INVESTOR CONFERENCE CALL INVITE

Q4 FY 2017-18

Syngene's Q4 & Full Year FY2018 Results Conference Call

At 3:00 pm IST on 26th April, 2018

The management team of Syngene International Limited ("Syngene") will organize a **conference call for Analysts and Investors on Thursday, 26th April at 3:00 pm IST** following the announcement of financial results for the quarter and year ended March 31, 2018.

The call will be initiated with a brief management discussion on the Q4 and Full Year FY2018 performance followed by an interactive Question & Answer session. Mr. Jonathan Hunt, Chief Executive Officer and other members of the senior management team will represent Syngene on the conference call.

Details of the conference call are as under:

Date:	Thursday, 26 th April 2018
Time:	3:00 pm to 4:00 pm IST
Dial-in Numbers:	
Primary Number	+91 22 7115 8180
Local Access Number	+91 70 4567 1221: Available all over India (Accessible from all carriers.)
International Toll Free Numbers	<ul style="list-style-type: none"> • USA – 18667462133/+13233868721 • UK – 08081011573/+442034785524 • Singapore – 8001012045/+6531575746 • Hong Kong – 800964448/+85230186877

INVESTOR CONFERENCE CALL INVITE

Q4 FY 2017-18

Pre-registration Facility	<p>Step 1: Pre-register here. You will receive a passcode and a pin for the call on the registered email address. The conference ID is 8287819.</p> <p>Step 2: Dial into the call on the Conference Call date, enter the passcode & pin as prompted. You will be directly connected to the call</p>
Replay Facility	<p>Dial in numbers: +91 22 7194 5757</p> <p>Playback ID: 65537</p> <p>The replay facility will be available from 26th Aril 2018 till 4th May 2018</p>
Conference Call Transcript	<p>Will be available within 7 working days of the call on the corporate website: www.syngeneintl.com</p>

About Syngene

Syngene International Limited, **(BSE code: 539268, NSE Id: SYNGENE, ISIN Id: INE398R01022)** is India's first Contract Research Organizations. It provides discovery and developmental services for new molecular entities across multiple platforms including Small Molecules, Large Molecules, Antibody-Drug Conjugates and Oligonucleotides. These services are aimed towards bringing novel molecules to the market by supporting the R&D efforts of organizations across diverse sectors like pharma, biotechnology, nutrition and animal health. In FY2017, Syngene serviced 293 clients including 8 of the top 10 global pharma companies (by FY2017 revenue). For more details, visit: www.syngeneintl.com

For further information, please contact:

Chanderlekha Nayar
 Syngene International
 ☎: +91 80 6775 8821 | Fax: +91 80 2852 3423
 ✉: Chanderlekha.Nayar@syngeneintl.com

Disclaimer: Certain of the statements that may be made or discussed at the conference call may be forward-looking statements and/or based on management's current expectations and beliefs concerning future developments and their potential effects upon Syngene and its associates. There can be no assurance that future developments affecting Syngene and its associates will be those anticipated by management. These forward-looking statements are not a guarantee of future performance and involve risks and uncertainties and there are important factors that could cause actual results to differ, possibly materially, from expectations reflected in such forward-looking statements. Syngene does not intend, and is under no obligation, to update any particular forward-looking statement made at the conference call.